C Lebrun loss rate over time in RIS patients? Can the rate of RIS brain volume loss be a herald of future disability or of cognitive worsening?) The improved understanding of RIS as an entity would provide clinicians with more tangible evidence on which to base the decision whether or not to start DMT in individual RIS patients. Until then, RIS as an entity requires much better characterization before starting DMT.
Radiologically isolated syndrome should be treated with disease-modifying therapy -Commentary Christine Lebrun
In this issue, D Okuda and A Labiano-Fontcuberta, together with J Benito-Leon, discuss the interesting issue of treating patients with radiologically isolated syndrome (RIS). This question alone raises the big issue of recognizing that this syndrome exists. In real-life practice, we should be able to identify people showing brain and spinal magnetic resonance imaging (MRI) fulfilling dissemination in space criteria, who have no history of symptoms of multiple sclerosis (MS) and a strictly normal neurological examination. 1, 2 Before asking about treatment, neurologists must ask specific questions about the diagnosis of RIS. Since the publications of the first French 3 and Turkish-American 2 RIS cohorts and the identification of a new acronym with specific diagnostic criteria, 1 a lot has been done to find evidence to push RIS to the very left limit of the demyelinating diseases spectrum. The worldwide effort made by the Radiologically Isolated Syndrome Consortium (RISC) has lead to describing the most important cohort of RIS, identifying prognostic markers for clinical conversion, either with relapsing 4 or progressive 5 symptoms. It appears that the risk at 5 years was 35%, with prognostic markers defined as age <37 years, male gender, or spinal cord lesions. An Italian team 6 has highlighted that non-conventional MRI sequences in RIS mirror the description of the very early stage of MS. All we know about the seminal event is that its repartition follows what we already know for clinically isolated syndrome (CIS) and that, once the patient suffers from neurological symptoms, the evolution mirrors prototypic forms of MS. 7 For D Okuda this argument is of major concern: we have to learn from the past and apply the treatment strategy "the earlier, the better." This policy stands for all chronic diseases. Nevertheless, the diagnosis of RIS is delicate and more than in MS, a source of over-diagnosis. 8, 9 As there is no clinical event to refer to, the main causes of overdiagnosis are (1) applying DIS radiological criteria for a patient who has a suspected clinical event suggestive of MS even when atypical based on the history; (2) an abnormal neurological examination; (3) inappropriate application of RIS diagnostic criteria, which have been validated using Barkhof and Tintore MRI criteria 10 and not the newest so-called Swanton criteria 11 used for MS; (4) over-reliance on the presence of MRI abnormalities meeting Barkhof and Tintore dissemination in space (DIS) criteria; and (5) mis-determination of lesion count, periventricular or juxtacortical lesion location.
Surveys on treatment practices have been done in the United States and in Europe. Neurologists are inclined to treat RIS patients if their follow-up MRI shows dissemination in time characterized with new gadoliniumenhancing lesions (for US neurologists 12 ) or spinal cord lesions (for European neurologists 13 ). Neither approach has been demonstrated or prospectively validated with a proper phase III study, even if we know that early disease-modifying treatment (DMT) introduction positively impacts the natural history of CIS patients. With these published surveys, the number of off-labeled treated RIS patients is increasing worldwide and current treatment patterns outside clinical studies are risky. The identified risk factors valid for RIS patients and the impact of DMT on radiological progression before the seminal event have not been demonstrated. This point is explained well by A Labiano-Fontcuberta. The risk/benefit profile of DMT has to be stratified according to the published risk factors. We do not know how many misidentified cases of RIS are receiving DMT, but no doubt the number will increase in the next few years, with an important undocumented repercussion on our health care systems. Worldwide collaboration is needed to improve characterization of RIS, with development of risk algorithms. We also have to increase the number of patients in a worldwide effort involving long-term prospective observation to determine how many patients will convert at 10 and 15 years and if the previously identified prognostic factors still stand. Neurologists will play a part in providing these answers when the two ongoing randomized, double-blind, placebo-controlled phases III studies assessing the ability of dimethyl fumarate (ARISE Study in the United States 14 ) or Teriflunomide (TERIS Study in Europe and Turkey 15 ) are published. Another aspect raised by this controversy is the need to explore how much the non-classical DMT drugs such as antibiotics (i.e. minocycline) or Vitamin D can influence the risk of clinical conversion. The history of RIS is one of the most beautiful examples of what can be done in record time in learning about a new syndrome when neurologists from everywhere around the world gather together their effort and knowledge in identifying patients who are at risk of developing a chronic disabling inflammatory disease.
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